Contemporary Use of Neuromuscular Blockade in Complex Patients - Maximizing Safety and Effectiveness
Critically ill patients may receive neuromuscular blocking agents (NMBAs) as adjunctive therapy in acute respiratory distress syndrome, shivering management, or for selected procedures, however, the use is less frequent than in the past. In addition, post-operative patients may experience residual blockade upon direct admission to the surgical intensive care unit (ICU). Awareness of the risks and management of NMBAs is important for ICU practitioners. Many aspects of patient management during continuous paralysis were addressed in the 2016 Society of Critical Care Medicine (SCCM) Guidelines for Sustained Neuromuscular Blockade, however, the use of a reversal agent was not included. This symposium will review the guidelines and discuss the role of NMBA reversal.
Agenda
Welcome and Introductions
Judith Jacobi, Pharm.D., BCCCP, DPNAP, FCCP, MCCM
Key Statements in the Society of Critical Care Medicine Guidelines on Neuromuscular Blockade
Judith Jacobi, Pharm.D., BCCCP, DPNAP, FCCP, MCCM
Patient Scenarios and Application of the Guidelines
Sean A. Nix, D.O., FACOS and
Judith Jacobi, Pharm.D., BCCCP, DPNAP, FCCP, MCCM
Faculty Discussion and Audience Questions
Learning Objectives
- Review key clinical practice statements from the 2016 Society of Critical Care Medicine (SCCM) Clinical Practice Guidelines for Sustained Neuromuscular Blockade in Critically Ill Adults.
- Apply the guidelines in patient case scenarios examining commonly administered neuromuscular blocking agents, their purpose, and potential side effects.
- Discuss strategies to minimize patient risk from residual neuromuscular blockade.
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in critical care and postoperative settings.
Format
This online activity consists of slide presentations, active learning, an assessment, and evaluation. View the system requirements.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, no persons associated with this activity have disclosed any relevant financial relationships.
Claim CE within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to complete the assessment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-0000-17-440-H01-P
Release Date: March 1, 2018
Expiration Date: May 21, 2019
Activity Type: Application-based
CE Credits: 1.5, no partial credit for pharmacists
Activity Fee: Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Judith Jacobi, Pharm.D., BCCCP, FCCP, MCCM, Pharm.D., BCCCP, DPNAP, FCCP, MCCM
Sean A. Nix, D.O., FACOS, D.O., FACOS